ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "ABP 798 and biosimilars"

  • Abstract Number: 537 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

    Gerd Burmester1, Edit Drescher 2, Pawel Hrycaj 3, David Chien 4, Zhiying Pan 4 and Stanley Cohen 5, 1Charité—University Medicine Berlin, Berlin, Germany, 22Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 3Koscian Municipal Hospital, Koscian, Poland, 4Amgen, Thousand Oaks, CA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.